Bio-Thera Solutions Licenses Cancer Drug Candidate to Saudi Arabia's Avalon Pharma
MT Newswires Live
Feb 04
Bio-Thera Solutions (SHA:688177) signed a deal granting Saudi Arabia's Avalon Pharma exclusive rights to commercialize its BAT3306 (pembrolizumab) for injection across the Middle East and North Africa.
The agreement includes an upfront payment of $2 million, milestone payments of up to $5 million tied to development progress and a double-digit percentage of future net sales, according to a Wednesday filing with the Shanghai bourse.
The deal covers a 15-year initial term with an automatic two-year renewal.
Pembrolizumab is a humanized monoclonal antibody drug used to treat cancer.
Shares of the pharmaceutical company closed 1% higher Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.